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Abstract 40 
Vaccination represents the most effective intervention to prevent infection, hospitalization and 41 
mortality due to influenza. This meta-analysis quantifies data reporting influenza vaccine 42 
effectiveness (VE) on influenza visits and hospitalizations of case-control and cohort studies among 43 
high-risk groups. 44 
A systematic literature review including original articles published between 2007 and 2016, using a 45 
protocol registered on Prospero with No. 42017054854, and a meta-analysis were conducted.  46 
For three high-risk groups (subjects with underlying health conditions, pregnant women and health 47 
care workers) only a qualitative evaluation was carried out. The VE quantitative analysis 48 
demonstrated a clear significant overall effect of 39% (95%CI: 32%-46%) for visits and 57% 49 
(95%CI: 30%-74%) for hospitalization among children. Considering the elderly influenza VE had a 50 
  
clear effect of 25% (95%CI: 6%-40%) for visits and 14% (95%CI: 7%-21%; p<0.001) for 51 
hospitalization. 52 
This study showed the high VE of influenza vaccination among high-risk groups, representing a 53 
tool for public health decision-makers to develop evidence-based preventive interventions to avoid 54 
influenza outcomes. 55 
 56 
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 91 
Introduction 92 
Influenza is a respiratory infectious disease responsible for thousands of infections, hospitalizations 93 
and deaths worldwide.
1-3
 Influenza viruses mainly affect lungs, higher and lower respiratory tract, 94 
representing one of the main causes of deaths and hospitalization especially during winter seasons. 95 
4,5
 In particular, higher morbidity and mortality rates were observed among the elderly, individuals 96 
with underlying health conditions, children and pregnant, that are particularly at risk for developing 97 
influenza complications, such as bacterial pneumonia.
6-11
 98 
At the same time, health care workers (HCWs) represent a group at higher risk of contracting 99 
influenza illness and transmitting the disease to their patients or to the general population.
12-14
 100 
Reported estimates of influenza infection among HCWs each season are various (ranging from 20% 101 
to 47.5%) and many of them continue working while infected,
13-15
 favoring the spread of influenza 102 
  
virus.
13
 For these reasons, hospitalized patients could acquire influenza not only from other patients 103 
or visitors but also from hospital employees and only high influenza vaccination coverage of health 104 
care personnel could prevent nosocomial influenza transmission, reducing influenza-like illness 105 
(ILI) mortality among more frail patients.
16,17
 106 
In general, influenza vaccination represents the most effective public health intervention to prevent 107 
seasonal influenza infection, hospitalization and mortality.
18-21
 All the preventive policies and 108 
international guidelines regarding influenza vaccination are primarily focused on protection of 109 
individuals at higher risk, by vaccinating themselves or those who could infect them.
19-21
 110 
The principal challenge of this systematic literature review is to analyze studies that reported 111 
influenza vaccine effectiveness (VE) data on reducing laboratory confirmed cases, hospitalization, 112 
morbidity or mortality due to influenza and to quantify its impact among high-risk groups.  113 
In particular the data were separately discussed among the following major high-risk groups 114 
identified in literature: children, subjects with underlying health conditions at any age, pregnant 115 
women, HCWs, and the elderly. 116 
 117 
Results 118 
 119 
Systematic literature review  120 
As illustrated in the flowchart (Figure 1), an initial number of 2,461 articles were retrieved through 121 
the selected databases. About one third of the manuscript (n=775/2,461) was identified as duplicates 122 
and removed. Through the initial screening of titles and abstracts 1,496 articles were excluded and 123 
overall 190 full text articles were assessed for eligibility. A total of 38 studies met all the inclusion 124 
criteria of which 13 were included in the qualitative synthesis, whereas 25 took place in the meta-125 
analysis (quantitative synthesis). For three major high-risk groups, namely subjects with underlying 126 
health conditions, pregnant women and HCWs, only a qualitative evaluation was conducted. Of 127 
note subjects with underlying health condition hadn’t the same comorbidities so they weren’t 128 
  
pooled together with meta-analysis. At the same time, both for two cohort studies about 129 
children/elderly and for case-control studies on pregnant women/HCWs (two studies for each high-130 
risk group), only a qualitative analysis was performed due to limited data available to conduct a 131 
quantitative evaluation. Out of the 25 remaining studies, two quantitative synthesis analyses were 132 
conducted for the high-risk groups of children and older people (12 manuscripts for children, 9 for 133 
the elderly, 4 conducted in both the high-risk groups). Table 1 describes the studies included both in 134 
qualitative or quantitative synthesis. In particular, 69% (n=25/36) of them referred to hospitalized 135 
patients, while 47% (n=17/36) were conducted in pediatric settings. Furthermore, 83% (n=30/36) of 136 
selected studies confirmed influenza vaccination status by at least one objective source of 137 
information (registries, electronic dataset, etc) and 78% (n=28/36) were case control studies 138 
conducted by using the test-negative design.  139 
 140 
Qualitative analysis 141 
Cohort studies conducted among children and the elderly 142 
Only two cohort studies examining effectiveness of influenza vaccine among children and the 143 
elderly were selected and included in the qualitative synthesis (Table 1). In particular, Szilagyi PG 144 
et al evaluated the effect of influenza vaccine on the number of outpatient visits and reported a VE 145 
range 7%-52% among children aged 6 to 59 months, during two consecutive influenza seasons 146 
(2003-2004 and 2004-2005) in three different American counties.
22 
On the other hand, a 147 
retrospective cohort study conducted among Ontario residents aged ≥65 years from 1993-1994 148 
through 2007-2008 seasons reported 22% VE for all influenza-associated deaths, 25% VE for 149 
deaths occurring within 30 days after and 19% VE for influenza-associated pneumonia/influenza 150 
hospitalization, respectively.
23
  151 
 152 
Subjects with underlying health conditions 153 
  
At the end of the revision process of studies that evaluated influenza VE in subjects with 154 
comorbidities, 5 case control and 2 cohort studies were selected and included in the qualitative 155 
analysis (Table 1). Cheng AC et al reported a 51.3% (95%CI: 40.7%-60.1%) reduction of 156 
hospitalization due to influenza disease in an Australian population (aged ≥18 years) with at least 157 
one chronic condition during 2014 season.
24
 In Sidney, a reduction of 83.6% (95%CI: 27.6%-158 
96.3%) for acute myocardial infarction hospitalization was reported, after influenza vaccination, 159 
among 599 adults with previous cardiovascular event from 2008 to 2010 influenza seasons.
25
 Also, 160 
among a Spanish group of subjects aged 18 years or older with high-risk conditions, was reported 161 
an adjusted VE of 53% (95%CI: 4%-77%) in reducing hospitalizations during the 2010–2011 162 
influenza season.
26
 Furthermore, a reduction of 49% (95%CI: 16%-69%) in hospitalization of a 163 
Dutch population 1-84 years old, with a diagnosis of laboratory confirmed A(H1N1)pdm09 164 
influenza and affected by at least one underlying medical condition (pulmonary or cardiac disease, 165 
diabetes mellitus, chronic kidney failure, cancer and immunocompromised condition), was 166 
observed in 2009-2010 season due to the adjuvanted pandemic vaccine,
27
 as also documented by 167 
Andrews N et al in reducing outpatient visits in England (62%; 95%CI: 33%-78%).
28
 168 
On the other hand, with regard to cohort studies on influenza vaccination effectiveness, Emborg HD 169 
et al reported a reduction of 49% on general practitioners (GPs) consultation, as well as 44% in 170 
hospitalization of subjects <65 years old with underlying chronic diseases in Denmark.
29
 Moreover, 171 
a study conducted among 64 Spanish solid organ transplant (SOT) recipient, reported an influenza 172 
VE of 85% (95%CI: 40%-97%) in reduction the hospitalizations during 2010-2011 season.
30
 173 
 174 
Pregnant women  175 
The qualitative analysis included two manuscripts on influenza VE among pregnant women (Table 176 
1). A population based case control study conducted in California and Oregon evaluated prevention 177 
of Polymerase chain reaction confirmed influenza cases, in pregnancy, and reported, using 178 
  
influenza-negative controls, a VE of 57% during the 2010-2011 season and 27% during the 2011-179 
2012 season, respectively.
31
 180 
Furthermore, a retrospective cohort study conducted in Western Australia among 34,701 pregnant 181 
women reported a VE of 81% (95%CI: 31%-95%) in decreasing emergency department visit for 182 
influenza and 65% reduction (95%CI: 3%-87%) in hospital admission of pregnant women, during 183 
the 2012 and 2013 influenza seasons.
32
 184 
 185 
Health care workers 186 
After the revision process only two manuscripts concerning influenza VE among HCWs were 187 
included in the systematic review (Table 1). In detail, a case control study reported a VE of 90.5% 188 
(95%CI: 73.5%-97.3%) in reducing emergency department visit for influenza A(H1N1), among the 189 
employees of Sao João Hospital of Porto during 2009-2010 season.
33
 Another study showed a VE 190 
of 70.5% in reducing influenza A(H1N1) hospitalization, among a cohort of Japanese HCWs during 191 
2009-2010 influenza season.
34
 192 
 193 
Quantitative analysis 194 
 195 
Children 196 
Overall, 7 of the 16 studies included in the meta-analysis evaluated the VE against influenza visits, 197 
while 9 focused on influenza hospitalization among children aged 6 months to 18 years. 198 
Considering outpatient or emergency department visits, VE demonstrated a clear significant overall 199 
effect of 39% (95%CI: 32%-46%) of influenza vaccines among cases when compared to control 200 
children (Figure 2). Since low heterogeneity was present between studies (I
2
=48.1%; p=0.052), for 201 
this analysis a fixed-effect model instead of a random-effect model was used. 202 
On the other hand, studies evaluating the overall influenza hospitalization VE were analyzed using 203 
random effect model. Indeed, using inverse-variance weighting to calculate fixed and random 204 
  
effects summary estimate, there was an higher moment base estimate between studies variance 205 
(Chi
2 
=0.40; p<0.001). The analysis on influenza hospitalization VE among children (Figure 2) 206 
showed a clear overall effect of 57% (95%CI: 30%-74%; p<0.001) even if with a higher between 207 
studies heterogeneity (I
2
=86.1%; p<0.001). To explain this phenomenon, a meta regression analysis 208 
was conducted including independent variables such as studies considering children (<9 years) 209 
vaccinated for the first time with at least two doses and hemisphere where the study was conducted. 210 
Moreover, other two independent variables integrated the meta regression analysis: mismatch 211 
between influenza A or B viruses included in vaccine and influenza viruses A or B circulating 212 
among cases and control. As a result, the log odds ratio of influenza hospitalization VE was 213 
estimated to decrease of 0.91 (p=0.043) among studies conducted in Northern hemisphere. The 214 
estimated between studies variance reduced from 0.40 to null. 215 
 216 
Elderly subjects 217 
There was a clear effect of 25% (95%CI: 6%-40%; p=0.012) using fixed effect model, when 218 
considering the 3 studies included in meta-analysis on VE for influenza visits among the elderly, 219 
although the heterogeneity between studies was very low (I
2
=0; p=0.864) (Figure 3). 220 
Additionally, among 10 studies considered about elderly a clear effect of 14% VE (95%CI: 7%-221 
21%; p<0.001) was observed in reducing hospital admission due to influenza with low 222 
heterogeneity between studies (I
2
=19.2%; p=0.286).  223 
 224 
Risk of bias across studies  225 
The symmetry of the funnel plots was examined in order to search for possible publication bias or 226 
even heterogeneity. Asymmetry was found for studies reporting influenza hospitalization VE 227 
among children (Table 2).  228 
 229 
Discussion  230 
  
This study provide an up-to-date review of VE on reducing measurable outcomes in health care, 231 
such as outpatient visits and hospitalization, among five of the most important high-risk groups to 232 
which was strongly recommended influenza vaccination.
35
 Other reviews beforehand conducted, 233 
demonstrated that considerable variations could be observed in reported influenza VE estimates due 234 
to differences in circulating viral strains among countries, proportion of influenza strains within one 235 
region, type of vaccine used, age-specific vaccine coverage, type of population studied, season 236 
definition, case definition, ascertainment of vaccination status, differences in surveillance time-237 
period, variables included or omitted in the statistical model, kind of model, and measured 238 
outcomes (admission, outpatient contact or infection).
36-38
 For these reasons, our study aimed to 239 
generate different model of systematic literature review (SLR) according to high-risk group 240 
considered, and to systematize the differences between other variables that make changing 241 
influenza VE. 242 
 243 
Qualitative analysis 244 
Subjects with underlying health conditions 245 
Subjects with underlying health conditions are recognized as a core group for influenza vaccination 246 
administration. Each co-morbidity represents a consistent increasing risk for influenza infection, 247 
complications and death. Furthermore, the association of several chronic conditions could enhance 248 
the risk for unvaccinated subjects during every influenza season.
18,39
 According to main public 249 
health authorities, all individuals >6 months old, with at least one chronic illness that represent a 250 
risk factor for influenza or complications, should be yearly and actively vaccinated against 251 
influenza.
21
  252 
In particular, some case-control studies among subjects with comorbidities reported similar VE 253 
values, in the qualitative synthesis analysis, for hospitalization reduction (around 50%) despite 254 
different influenza seasons considered.
24,26,27
 Moreover, a reduction of 62% in outpatient visits and 255 
84% in acute myocardial infarction hospitalization after influenza vaccination was demonstrated, as 256 
  
described by other authors.
25,28,40
 Also a cohort study conducted in Denmark reported a similar VE 257 
value (44%) in reducing hospitalization, while another cohort study among SOT found an higher 258 
value of VE (85%), evidencing the key role of influenza vaccination in preventing hospitalization in 259 
this particular high-risk group.
29,30,41
  260 
 261 
Pregnant women 262 
Both studies analyzed in the SLR conducted among pregnant women demonstrated a good VE in 263 
decreasing the total number of laboratory confirmed influenza cases,
31 
emergency department visits 264 
and hospitalizations in different influenza seasons.
32 
The consistent difference of VE among 265 
vaccinated pregnant women observed in US between the seasons 2010-2011 and 2011-2012 could 266 
be due to residual or unmeasured confounding, even if it was similar when stratified by season and 267 
influenza virus type.
31
 The magnitude effect of influenza vaccination during pregnancy was 268 
justified especially by two main factors: the rapid clinical deterioration observed in some patients in 269 
respect to the typical course of seasonal influenza, especially when infected with A(H1N1)pdm09 270 
strains,
9,42
 and the higher prevalence of cleft lip–palate, neural-tube defects and cardiovascular 271 
malformations in newborns of mother with confirmed diagnosis of influenza during the second 272 
and/or third month of pregnancy.
43
  273 
 274 
Heath care workers 275 
Influenza vaccination of HCWs is the most effective public health strategies for preventing 276 
nosocomial influenza transmission and reducing ILI mortality among elderly and high-risk patients, 277 
as well as for minimizing absenteeism during annual epidemics.
12,14,16,18
  278 
The two studies included in the SLR throughout the qualitative synthesis were both related to VE 279 
during the pandemic influenza season and the use of adjuvanted monovalent influenza vaccine 280 
against A(H1N1)pdm09.
33,34
 The very high level of VE in reducing emergency department visits 281 
and hospitalization for influenza A(H1N1)pdm09 confirmed the specific tropism of pandemic 282 
  
influenza strains for younger people but also the very high efficacy of the influenza vaccines 283 
quickly developed worldwide.
44,45 
 284 
 285 
Quantitative analysis 286 
Children 287 
During each seasonal outbreak, children sustain the highest burden of influenza. A systematic 288 
review of the global disease burden of influenza in children >5 years estimated that there were 90 289 
million (95%CI: 49–162 millions) cases during the 2008 influenza season, 20 million (95%CI: 13–290 
32 millions) cases of influenza-associated acute lower respiratory infections (ALRI), and 1–2 291 
million cases of influenza associated severe ALRI, including 28,000 - 111,500 deaths.
46
 A review 292 
from 1982 to 2012, estimated that influenza resulted in approximately 374,000 (95%CI: 264,000 - 293 
539,000) hospitalizations in children <1 year old, of which 228,000 (95%CI: 150,000 - 344,000) 294 
occurred among children <6 months, and 870,000 (95%CI: 610,000 - 1,237,000) in children <5 295 
years of age, annually.
47
 According to data of this meta-analysis, influenza vaccination was 296 
protective against outpatient visits among children, especially considering studies with children <9 297 
years old and in the US, with a confirmed vaccination status. The lower value of VE for outpatient 298 
influenza visits among children, were found by Sullivan SG et al.
48
 This latter could be due to 299 
unadjusted VE by distance of influenza visits and influenza vaccine administration. A combination 300 
of two possible mechanisms could explain this reduced VE. Firstly, seasonal variations of 301 
circulating viruses, due both to the appearance of another virus type or to the antigenic drift of 302 
circulating strains, could be responsible of a partial vaccine mismatch.
49
 Secondly, a waning 303 
immunity one month after administration of the influenza vaccine was described even among 304 
children.
50
 Furthermore, to assess vaccination status of enrolled children, this study used a not 305 
confirmed method, and this could further reduce the specificity of results on vaccination status. In 306 
particular, a study suggested that specificity of self-reported influenza vaccination status can be 307 
  
lowest for young children, whose parents may easily confuse influenza vaccine with other routine 308 
childhood vaccines.
49
 309 
Better results about influenza visits VE were reported by Eisemberg KW et al,
50
 that estimated the 310 
influenza VE for children during the 2003-2004 and 2004-2005 seasons, although the matching 311 
between circulating influenza viruses and those included in the vaccine was considered suboptimal 312 
for both seasons.
51,52
 313 
A better VE was found in reduction of influenza hospitalizations than outpatient influenza visits. 314 
Among studies focusing influenza hospitalization VE, the majority were conducted among children 315 
aged 6 months to 17 years, in Northern hemisphere, with diagnosis of influenza A or B infection 316 
and with a confirmation of vaccination status. Only studies conducted in Southern hemisphere were 317 
associated with an increase of influenza hospitalization VE, and this result can be explained because 318 
more frequently patients of studies conducted in Southern hemisphere were recruited from tertiary 319 
pediatric referral hospital as in Blyth CC et al and Dixon GA et al.
53,54
 These studies may have 320 
included more severe infections or complicated comorbidities, when compared to children admitted 321 
to more general pediatric wards. Furthermore, a recent global estimates of hospitalization for acute 322 
lower respiratory infections, among children <17 years old, including data from systematic review 323 
and surveillance platforms, showed that pooled percentages of positivity for influenza among 324 
hospitalized children with respiratory illness, varied among World Health Organization (WHO) 325 
regions with the highest values in Western Pacific and Southeast Asia (8.5% in both cases) and the 326 
lowest in the Americas and Europe (4.6% and 7.1%, respectively).
47
 These data confirm a different 327 
frequency of severe influenza illness between Southern and Northern hemispheres that could 328 
partially explain the VE variability. Even if differences in hospitalization practices, applications of 329 
case definitions and factors, such as time from symptom onset to specimen collection, could make 330 
detection of influenza viruses more or less likely, and therefore this could bias the outcome. 331 
 332 
Elderly subjects 333 
  
All of the three studies included in VE analysis and concerning the reduction of outpatient visits 334 
were conducted among confirmed influenza A and B individuals aged >65 years. More frequently 335 
were conducted in Northern hemisphere and the confirmation of influenza vaccine status collected 336 
through registries. The better influenza VE among elderly was found in Sullivan SG et al even with 337 
any limitations.
48
 In particular, these authors did not adjust for distance of influenza visit and 338 
influenza vaccine administration, and did not collect data on the presence of comorbidities 339 
predisposing to severe influenza, such as asthma, obesity and immunocompromising conditions.
48
 340 
Failure to adjust for this important confounder may have accounted for the unexpected age effects. 341 
In these patients many mechanisms of failed response were related to frailty driven by chronic 342 
inflammation and age, even if one more established, but still controversial, explanation is the 343 
concept of original antigenic sin.
55
 This means that previous exposure to an antigen resulted in a 344 
sub-standard immune response, when exposure to a novel but closely related antigen occurs.
56
 345 
In McLean HK et al was found a lower value of influenza visits VE among elderly, in particular for 346 
influenza A(H3N2).
11
 This estimated VE was consistent with laboratory findings from the US 347 
national virological surveillance during the same influenza season.
57
 Although virological 348 
surveillance indicated no antigenic drift between the circulating influenza A(H3N2) viruses and the 349 
cell grown reference vaccine virus, the egg-propagated A/Victoria/361/2011 reassortant virus used 350 
in vaccine production acquired 3 amino acid changes in the antigenic region of HA (at positions 351 
H156Q, G186V and S219Y), which significantly altered its antigenicity.
57
 Furthermore, this low 352 
VE against A(H3N2) suggests that other factors in addition to immunosenescence, may be 353 
important modifiers in this age group.
55
 In particular, additional studies are needed to understand 354 
the impact of previous infections, vaccinations, and antigenic variability on the risk of illness.
58
 355 
In the elderly influenza VE was lower in hospitalization than outpatient visits. The studies reported 356 
in the meta-analysis of influenza hospitalization VE were more frequently among people >65 years 357 
old, conducted in Northern hemisphere and regarding trivalent inactivated influenza vaccines. The 358 
better influenza hospitalization VE was found by Orellano PW et al,
59
 even if socioeconomic status, 359 
  
place of residence, medical consultation, or past hospitalizations were not included in this study. 360 
This means that severe or mild influenza cases may be different in terms of background 361 
characteristics, and this might bias the estimated VE.
55
 362 
On the other hand, lower influenza hospitalization VE was revealed by Gilca R et al.
60
 This can be 363 
consistent with mismatch during 2014-2015 influenza season, when the majority of A/H3N2 strains 364 
circulating in the Northern hemisphere were antigenically mismatched to the A/Texas/50/2012 365 
H3N2 vaccine strain.
61
 Furthermore, hospitalization VE was evaluated considering a self-reported 366 
vaccination status and this may have resulted in exposure misclassification.
49
  367 
Only three studies reporting VE among elderly who received adjuvanted vaccine did not calculate 368 
VE by vaccine type.
26,60,72 
The authors justified this due to small number of elderly vaccinated with 369 
adjuvanted vaccine compared to other trivalent inactivated vaccine. In future, would be beneficial 370 
that seasonal VE estimates will be reported by vaccine type to facilitate valid comparisons. 371 
Limits  372 
The studies included in the meta-analyses suffer from a limitation due to a potential overestimation 373 
of the vaccination status that could have occurred, since some examined studies used partially or 374 
totally referred vaccination status without validation technique. This could assess subjective 375 
measures of vaccine uptake that cause recall bias (e.g. past influenza vaccination uptake can be 376 
confused with the current one). Investigators who rely on self-reported influenza vaccination status, 377 
in particular for young children, should consider the possibility that up to 10% of individuals may 378 
be misclassified. So, whenever feasible, vaccination data should be validated by an external source 379 
to reduce misclassification.
49
 380 
Also, a possible limit of the present study could be the different vaccine policies and strategies 381 
adopted in various countries, as well as the different type of influenza vaccines routinely available. 382 
All these factors could have influenced VE reported in different areas. 383 
  
Regarding asymmetry resulted with influenza hospitalization VE among children, the analysis of 384 
funnel plot showed that missing studies were in a top right and bottom left area of significance, so 385 
publication bias was unlikely to be the underlying cause of asymmetry. 386 
 387 
Conclusion 388 
Influenza represents one of the leading causes of death worldwide. In particular, children, older 389 
people, subjects with underlying health conditions, pregnant women and health care workers are 390 
groups at higher risk of contracting influenza infection and its complication. Worldwide, 391 
vaccination constitutes the only recognized strategy to prevent the spread of influenza viruses as 392 
well as human-to-human transmission and infection, and the most important public health 393 
authorities strongly recommended vaccine administration among these high-risk groups. 394 
Our SLR and meta-analysis demonstrated the high VE of influenza vaccination in all these high-risk 395 
groups, often regardless of season, circulating strain, type of vaccination. Furthermore, the 396 
reduction in hospitalization and outpatient visits represent not only a health benefit for individuals 397 
vaccinated but also an essential profit for National Health Systems. 398 
Finally, may be suitable that this SLR and meta-analysis aim to provide a tool for public health 399 
decision makers in order to develop evidence based preventive interventions to contrast influenza 400 
infection, especially among high-risk groups. 401 
 402 
Material and methods 403 
 404 
Systematic literature review 405 
A SLR was carried out on influenza VE among high-risk groups. They, according to WHO position 406 
paper, were identified as people at increased risk of exposure to influenza virus as well as those at 407 
particular risk of developing severe disease (i.e. older people, children, people suffering from 408 
comorbidities and pregnant women).
35
 A written protocol was supplied to all investigators recruited, 409 
  
before starting SLR, and it was registered on Prospero with No. 42017054854 on 19 January 2017. 410 
Case-control and cohort studies on influenza health care outcomes, between vaccinated and 411 
unvaccinated risk groups, were selected through a SLR using key terms in combination and referred 412 
to vaccine/immunization, effectiveness, impact, at risk people and influenza/flu, with medical 413 
Subject Headings (MeSH) and MeSH Major Topics included in the syntax. The online databases 414 
PubMed/MEDLINE, SCOPUS, EMBASE, ISI Web of Science were considered, as well as the gray 415 
literature and a manual search from the references of the articles retrieved and it was performed in 416 
January 2017. 417 
Original articles published between 1
st
 of January 2007 and the 31
st
 of December 2016 were 418 
retrieved, with restriction criteria applied: articles published in the English language and concerning 419 
influenza effectiveness in risk groups. Among all high-risk groups considered, elderly subjects (≥50 420 
years old), children (≤18 years old), subjects with underlying health conditions at any age, pregnant 421 
women and HCW were included in the SLR. All influenza vaccines recommended by the WHO 422 
were considered to evaluate VE: trivalent inactivated vaccines and live attenuated influenza 423 
vaccines.
35
 For inclusion, studies were required to focus on at least one countable outcome related 424 
to influenza infection: GP or emergency department visits, hospital admission or death. Information 425 
were collected from patient consulting medical facilities or medical databases reporting health care 426 
outcomes. The following exclusion criteria were also applied during title and abstract screening: 427 
articles published in languages other than English, reporting only vaccination information, assessing 428 
only vaccination coverage, reporting only vaccination uptake determinants and review articles, 429 
trials and qualitative studies. 430 
Other exclusion criteria used during full-text analysis were: no reporting VE, reporting overall VE 431 
not specifically defined for high-risk-groups considered in the review, reporting VE not in high-432 
risk-groups and reporting VE on hospitalization or outpatients visit for ILI or acute respiratory 433 
infection. Only quantitative studies describing influenza VE among risk-groups were included in 434 
the review. Studies were then selected for the qualitative and quantitative analysis. 435 
  
Variables extraction regarded: cases of influenza among high-risk-groups considered in the SLR, 436 
influenza VEs in selected group, laboratory diagnostic procedures for testing for influenza and 437 
strategies used to assess vaccination status of each participant. Four investigators independently 438 
conducted both a literature search and a systematic review considering the inclusion, eligibility 439 
criteria and quality. Incongruity between the investigators was resolved by further discussion, with 440 
involvement of an external investigator where necessary. 441 
 442 
Meta-analysis 443 
After studies have been selected, reporting number of vaccinated among cases and control and/or 444 
influenza incident cases among exposed and unexposed to influenza vaccine, a meta-analysis 445 
according to Cochrane guidelines,
62
 was conducted on the extracted measures in order to assess the 446 
overall effect. Crude ORs and RRs were considered where available. The logarithms were used for 447 
the meta-analysis, with exponentiated effect sizes and confidence intervals displayed in the forest 448 
plots. Vaccine effectiveness was calculated as VE = [(1-OR)x100] or VE = [(1-RR)x100] and crude 449 
ORs or RRs with relative 95% Confidence Interval (95%CI) were estimated for each risk-group.
63
 450 
Pooled estimates were calculated using both fixed effects and DerSimonian and Laird random 451 
effects models, weighting individual study results by the inverse of their variances.
64
 Forest plots 452 
were used to visually assess the pooled estimates and corresponding 95%CI across studies. A test of 453 
heterogeneity was performed using a chi-square test at significance level of p<0.05 and reported 454 
with the I
2
 statistic together with a 25%, 50% or 75% cut-off, indicating low, moderate and high 455 
heterogeneity, respectively.
65,66
 456 
When the test showed significant heterogeneity, the sources of heterogeneity were explored through 457 
pre-specified meta-regression and sensitivity analyses. The following variables were considered for 458 
a meta-regression analysis: vaccinated children (<9 years old) who performed, for the first time, 459 
two doses of influenza vaccination (yes vs no), hemisphere where study was conducted (Northern vs 460 
Southern), year of study conduction before or after influenza pandemic season (before 2010 vs after 461 
  
2010) and two variables that reported mismatch between influenza A or B viruses included in the 462 
seasonal vaccine and circulating viruses among cases and controls or exposed and unexposed (yes 463 
vs no), respectively. Sensitivity analyses were conducted to examine the contribution of each 464 
individual study by evaluating the impact of the outlier studies, eliminating each study from the 465 
meta-analysis and comparing the point estimates which included or excluded the study. 466 
The methodological quality of studies included in the meta-analysis was assessed using revised 467 
versions of previously validated checklists for quantitative retrospective and prospective studies, as 468 
recommended by the Cochrane Collaboration.
62,67
  469 
To assess a potential publication bias, a graphical plot of the logarithm effect estimates versus its 470 
standard error, for each study, was employed, and the Egger test was performed.
68,69
  471 
All data were analyzed using the statistical package STATA/MP 14.2 (StataCorp LP, College 472 
Station, TX, USA), with the “metan” command used for meta-analysis, “metafunnel”, “metabias” 473 
and “confunnel” for publication bias assessment.70 474 
  475 
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Table 1: Characteristics of included studies on anti-influenza vaccine effectiveness among at risk-group  
Reference 
article 
At risk-
group 
Outcome 
Publication 
year 
Influenza season Age range 
Sample 
size 
Country 
Influenza vaccine 
type 
Influenza virus 
diagnsosis among 
cases 
Vaccine 
status 
Study design 
Qualitative/Quantit
ative analysis 
Szilagyi PG22 children 
outpatient 
visit 
2008 
from 2003-2004 to 
2004-2005 
from 6 months to 6 
years 
10,906 US trivalent inactivated A(H3N2) Confirmed Cohort Qualitative 
Ridenhour BJ23 older 
hospitalizati
on/ deaths 
2013 
from 1993-1994 to 
2007-2008 
≥ 65 years 21,180,919 Canada N.A. N.A. Confirmed Cohort Qualitative  
Andrews N28 comorbidity 
outpatient 
visit 
2011 2009-2012 <5 and ≥ 65 years 2,153 UK adiuvated pH1N1  A(H1N1) Confirmed Case-control Qualitative 
Emborg HD29 comorbidity 
outpatient 
visit / 
hospitalizati
on 
2011 2009-2010 <65 years 388,069 Denmark adiuvated pH1N1  A(H1N1) Confirmed Cohort Qualitative  
MacIntyre CR25 comorbidity 
hospitalizati
on 
2013 from 2008 to 2010 ≥ 18 years 599 Australia trivalent inactivated A and B Confirmed Cohort Qualitative  
Perez-Romero 
P30 
comorbidity 
hospitalizati
on 
2012 2010-2011 >16 years 64 Spain trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed Cohort Qualitative  
Steens A27 comorbidity 
hospitalizati
on 
2011 2009-2011 from 1  to 84 years 10,968 Netherlands adiuvated pH1N1  A(H1N1) Confirmed Case-control Qualitative 
Thompson 
MG31 
pregnant 
women 
outpatient 
visit 
2013 
2010-2011 and 
2011-2012 
from 22 to 38 years 492 US trivalent inactivated A(H1N1) Confirmed Case-control Qualitative  
Regan AK32 
pregnant 
women 
outpatient 
visit / 
hospitalizati
on 
2016 2012-2013 ≥ 18 years 2,962,374 Australia trivalent inactivated A(H1N1) Confirmed  Cohort Qualitative 
Costa JT33  
health care 
workers 
outpatient 
visit 
2012 2009-2010 ≥ 18 years 245 Portugal adiuvated pH1N1  A(H1N1) Confirmed Case-control Qualitative 
Igari H34 
health care 
workers 
hospitalizati
on 
2011 2009-2013 ≥ 20 years 1,817 Japan adiuvated pH1N1  A(H1N1) Confirmed Cohort Qualitative 
Blyth CC71 children 
outpatient 
visit 
2016 
2008 and from 2010 
to 2013 
from 6 months to 18 
years 
2,205 Australia trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed  Case-control Quantitative  
Sullivan SG48 children and outpatient 2014 2012 < 18 and >65 years 488 Australia trivalent inactivated A(H1N1), A(H3N2) Not Case-control Quantitative  
  
older visit and B confirmed 
Mc Lean HK72 
children and 
older 
outpatient 
visit 
2014 2012-2013 
from 6 months to 17 
years and ≥65 years 
3,145 US 
trivalent inactivated, 
adiuvated and live 
attenuated 
A(H1N1), A(H3N2) 
and B 
Confirmed Case-control Quantitative 
Belongia EA73 children 
outpatient 
visit 
2011 2007-2008 
from 6 months to 6 
years 
412 US trivalent inactivated 
A(H3N2) and B 
Yamagata 
Confirmed Case-control Quantitative  
Joshi AY74 children 
outpatient 
visit 
2009 
from 1999-2000 to 
2006-2007 
from 6 months to 6 
years 
206 US trivalent inactivated 
A(H1N1), A(H3N2) 
and B Victoria 
Confirmed Case-control Quantitative  
Eisenberg 
KW50 
children 
outpatient 
visit  
2008 
from 2003-2004 to 
2004-2005 
from 6 months to 6 
years 
2,534 US trivalent inactivated N.A. Confirmed Case-control Quantitative 
Shuler CM75 children 
outpatient 
visit 
2007 2003-2004 
from 6 months  
to 6 years 
870 US trivalent inactivated N.A. Confirmed Case-control Quantitative 
Chiu SS76 children 
hospitalizati
on 
2016 
from 2009-2010 to 
2013-2014 
from 6 months to 17 
years 
6,257 Hong Kong trivalent inactivated 
B Yamagata and B 
Victoria 
Not 
confirmed 
Case-control Quantitative  
Blith CC54 children 
hospitalizati
on 
2015 
2009 and from 2010 
to 2014 
from 6 months to 6 
years 
712 Australia trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed  Case-control Quantitative 
Grijalva CC 77 
children and 
older 
hospitalizati
on 
2015 
from 2009-2010 to 
2011-2012 
from 6 months to 17 
years and ≥65 years 
1,806 US 
pandemic, trivalent 
inactivated and live 
attenuated 
A(H1N1), A(H3N2) 
and B 
Confirmed  Case-control Quantitative  
Cowling BJ78 children 
hospitalizati
on 
2014 
from 2009-2010 to 
2012-2013 
from 6 months to 17 
years 
5,399 Hong Kong 
pandemic and 
trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Not 
confirmed 
Case-control Quantitative 
Ferdinands 
JM79 
children 
hospitalizati
on 
2014 
from 2010-2011 to 
2011-2012 
from 6 months to 17 
years 
309 US N.A. 
A(H1N1), A(H3N2) 
and B 
Confirmed Case-control Quantitative  
Gilca R80 children 
hospitalizati
on 
2011 2009-2010 
from 6 months to 9 
years 
884 Canada adiuvated pH1N1  pH1N1 Confirmed Case-control Quantitative 
Griffin MR81 children 
hospitalizati
on 
2011 2009-2010 
from 6 months to 9 
years 
2,168 US 
live attenuated and 
inactivated pH1N1  
pH1N1 Confirmed Case-control Quantitative 
Dixon GA53 children 
hospitalizati
on 
2010 2008 
from 6 months to 6 
years 
76 Australia trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed Case-control Quantitative  
Orellano PW59 
children and 
older 
hospitalizati
on 
2010 2009 
<5 years and >65 
years 
1,115 Argentina trivalent inactivated pH1N1 Confirmed Case-control Quantitative  
Chen Q82 older outpatient 2014 from 2006-2007 to ≥ 65 years 927 US trivalent inactivated A(H1N1), A(H3N2) Confirmed Case-control Quantitative  
  
 
 
 
 
 
 
 
 
 
visit 2008-2009, from 
2010-2011 to 2011-
2012 
and B 
Havers F83 older 
hospitalizati
on 
2016 2010-2011 >50 years 1,141 US trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Not 
confirmed 
Case-control Quantitative  
Cheng AC24 
older and 
comorbidity 
hospitalizati
on 
2015 2014 
>65 years and ≥16 
years for 
comorbidity 
3,217 Australia trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Not 
confirmed 
Case-control Quantitative  
Gilca R60 older 
hospitalizati
on 
2015 2014-2015 ≥ 65 years 314 Canada 
adiuvated trivalent 
inactivated 
A(H3N2) 
Not 
confirmed 
Case-control Quantitative  
Puig-Barberà 
J84  
older 
hospitalizati
on 
2015 2014- 2015 ≥ 65 years 1,108 Spain trivalent inactivated A(H3N2) Confirmed  Case-control Quantitative 
Castilla J85 older 
hospitalizati
on 
2014 2013-2014 >65 years 239 Spain trivalent inactivated 
A(H1N1) and 
A(H3N2) 
Confirmed Case-control Quantitative  
Kwong JC86 older 
hospitalizati
on 
2013 2010-2011 >65 years 2,230 Canada trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed Case-control Quantitative  
Puig-Barberà 
J26  
older and 
comorbidity 
hospitalizati
on 
2012 2010-2011 
>60 years and ≥18 
years for 
comorbidity 
379 Spain 
adiuvated trivalent 
inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed Case-control Quantitative 
Van Vuuren A87 older 
hospitalizati
on 
2008 2004-2005 ≥ 65 years 6,410 South Africa trivalent inactivated 
A(H1N1), A(H3N2) 
and B 
Confirmed Case-control Quantitative  
  
 
 
 
  
 
Table 2: Analysis for funnel plot asymmetry of studies reporting vaccine effectiveness, estimated by Egger’s regression test 
 
 
 No. studies coefficient 95% CI p-value 
Vaccine effectiveness on influenza visits among children 9 -0.78 -3.51 1.94 0.520 
Vaccine effectiveness on influenza hospitalization among children 10 -3.05 -5.93 -0.18 0.040 
Vaccine effectiveness on influenza visits among elderly subjects 3 -1.06 -16.41 14.29 0.541 
Vaccine effectiveness on influenza hospitalization among elderly subjects 10 -0.52 -2.35 1.31 0.531 
  
  
  
 
 
 
 
 
 
